BioCentury | Jun 21, 2019
Company News

June 20 Company Quick Takes: Priority Review for Alexion, Melinta therapies; plus Alimera, Denovo and more

Priority Review for Alexion's Ultomiris sBLA FDA accepted and granted Priority Review to an sBLA from Alexion Pharmaceuticals Inc. (NASDAQ:ALXN) for Ultomiris ravulizumab-cwvz to block complement-mediated thrombotic microangiopathy in patients with atypical hemolytic uremic syndrome....
BioCentury | Dec 23, 2013
Company News

Orion, J&J deal

Orion granted Johnson & Johnson's Janssen Pharmaceuticals Inc. subsidiary exclusive, worldwide development rights and ex-European commercialization rights to Orion's adrenergic receptor alpha 2c ( ADRA2C ) antagonists to treat Alzheimer's disease (AD). The deal includes ORM-12741 , which...
BioCentury | Dec 20, 2013
Company News

Orion, J&J in Alzheimer's deal

Orion Corp. (HSE:ORNAV; HSE:ORNBV) granted the Janssen Pharmaceuticals Inc. subsidiary of Johnson & Johnson (NYSE:JNJ) exclusive, worldwide development rights and ex-European commercialization rights to Orion's adrenergic receptor alpha 2c ( ADRA2C ) antagonists to treat Alzheimer's disease....
BioCentury | Apr 1, 2013
Clinical News

ORM-12741: Phase IIa data

A double-blind, Finnish Phase IIa trial in 100 patients with moderate AD and behavioral symptoms showed that twice-daily flexible dosing with 30-60 mg or 100-200 mg ORM-12741 as an add-on to stable cholinesterase inhibitor therapy...
BioCentury | Aug 18, 2008
Clinical News

Alpha 2c receptor antagonist: Phase I started

This summer, Orion began a Phase I trial in healthy volunteers. Orion Corp. (HSE:ORNAV; HSE:ORNBV), Espoo, Finland Product: Alpha 2c receptor antagonist Business: Neurology Molecular target: NA Description: Selective adrenoceptor alpha 2c antagonist Indication: Treat...
Items per page:
1 - 5 of 5